骨髓增生异常综合征预后评价指标研究新进展

Research Progress of Prognostic Indexes in Myelodysplastic Syndrome

骨髓增生异常综合征(MDS)是一组复杂的造血系统疾病,其复杂性不仅体现在疾病本身,还体现在疾病进展及预后上。目前MDS的诊断已形成明确的组织病理学标准,而预后的判断主要包括临床特征、骨髓形态学表现、细胞遗传学及分子生物学特性等几个方面。其中以国际预后评分系统应用最为广泛,但该系统对MDS的预后评价也具有一定局限性,因此目前对该病的预后判断尚未形成全面而统一的标准。近年来一些新的预后评价系统、细胞遗传学及血清学改变对MDS预后影响的研究都取得较大进展。

Myelodysplastic syndromes（MDS）is a group of complicated hematopoietic system disease,and its complexity relates not only to the characteristics,but also to the progression and prognosis of the disease.At present,the diagnosis of MDS has already formed a well-established histopathological criteria,while prognosis estimate of the disease has not established a unified standard.Indexes of prognosis in use include clinical characteristics,morphological features,cytogenetics and molecular characteristics.Although,the most widely used prognostic classification system is the International Prognostic Scoring System（IPSS）,the system has several limitations.In recent years,study of new prognostic system,genetics and serologic changes for prognostic of MDS have made considerable progress.